Navigation Links
Vicus Therapeutics to Present at the BMO Capital Markets Focus on Healthcare Conference

MORRISTOWN, N.J., Dec. 3 /PRNewswire/ -- Vicus Therapeutics, LLC, an oncology-focused, clinical-stage biopharmaceutical company, announced today that Chief Executive Officer, John Maki, will present at the BMO Capital Markets Focus on Healthcare Conference. The presentation will be held on December 4, 2007 at 1:30 p.m. ET at the Millennium Broadway Hotel in New York City.

About Vicus Therapeutics

Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' strategy involves combining individual generic drugs that have previously received regulatory approval for other indications and thus have established post-marketing safety records. Vicus leverages its proprietary science to design and patent novel drug combinations that work together to reverse the body's maladaptive responses to cancer and its treatment. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue. Vicus' development programs are powered by its network of leading clinical investigators and partners in the US, India and Japan. This international network drives the high quality, rapid and cost effective clinical development of Vicus' product candidates. For additional information, go to the Company's website:

SOURCE Vicus Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Vicus Therapeutics Chief Executive Officer to Participate in BIOTECH 2007 Expert Panels
3. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
4. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
5. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
6. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
7. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
8. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
9. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
10. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
11. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
Post Your Comments:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... June 23, 2016 A person commits a crime, ... scene to track the criminal down. An outbreak ... and Drug Administration (FDA) uses DNA evidence to track down ... Sound far-fetched? It,s not. The FDA has increasingly used ... investigations of foodborne illnesses. Put as simply as possible, whole ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , a ... $1 million in debt financing from Silicon Valley Bank ... automation and to advance its drug development efforts, as ... facility. "SVB has been an incredible strategic ... services a traditional bank would provide," said Dr. ...
Breaking Biology Technology:
(Date:6/22/2016)... LOS ANGELES , June 22, 2016 ... of identity management and verification solutions, has ... cutting edge software solutions for Visitor Management, ... ® provides products that add functional ... The partnership provides corporations and venues with ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/16/2016)... June 16, 2016 The ... expected to reach USD 1.83 billion by 2024, ... Research, Inc. Technological proliferation and increasing demand in ... expected to drive the market growth. ... The development of advanced multimodal techniques for ...
Breaking Biology News(10 mins):